|
Market Closed -
Nasdaq
21:00:00 01/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 29.02 USD | -1.39% |
|
-6.48% | +4.69% |
| 09-01 | Beam Therapeutics Inc. Appoints Eric Foster as Chief Commercial Officer | CI |
| 08-19 | Ultragenyx's gene therapy wins first FDA approval for rare metabolic disorder | RE |
Chart: Technical Analysis
Stock exchange
Nasdaq
BEAM 29.02 $
-1.39%
25.81M
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Nasdaq
| BEAM | 29.02USD | -1.39% | 25.81M $ | |
CBOE
| BEAM | 29.03USD | -1.33% | 502K $ | |
|
Mexican S.E.
| BEAM * | 500.00MXN | +10.13% | 20K $ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Neutral |
| Resistance | 31.03 | 37.92 | 34.81 |
| Spread/Res. | -6.48% | -23.47% | -16.63% |
| Spread/Supp. | +2.36% | +32.51% | +33.61% |
| Support | 28.35 | 21.9 | 21.72 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- BEAM Stock
- Charts Beam Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
